Press Releases

Month Year

Sep 30, 2021

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis
Aug 12, 2021

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update

Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022
Aug 9, 2021

Trevi Therapeutics Announces Additions to the Senior Leadership Team

Key Management Appointments Support Company Growth as Lead Trials Move Towards Data
Aug 5, 2021

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12

Conference Call and Webcast to be Held at 4:30 p.m. ET
Jun 9, 2021

Trevi Therapeutics to Present at 2021 BIO Digital Conference

Show per page

Media Contact

Katie Barrett
(203) 903-9627
k.barrett@trevitherapeutics.com

Trevi Therapeutics
195 Church Street, 16th Floor
New Haven, CT 06510
map